Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

Stacy Gray, M.D. Receives NIH Grant for Cancer Genomics Research

September 11, 2019 | Letisia Marquez

Stacy Gray, M.D., associate clinical professor in the Division of Clinical Cancer Genomics, is one of six physicians to receive an inaugural “Genomic Innovator Award” from the National Human Genome Institute (NHGI).

Innovative approach using KITE-439 in targeting HPV-related malignancies

August 20, 2019 | City of Hope

HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.

ET140202 Artemis T Cell therapy for the treatment of liver cancer

August 20, 2019 | City of Hope

City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that eventually could transform treatment of the usually fatal disease into an outpatient procedure.

PSCA as a novel CAR T target for resistant prostate cancer

August 20, 2019 | City of Hope

In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.

Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

ASCO research highlights: First KRAS inhibitor and CAR T cell therapy for CLL

June 28, 2019 | City of Hope

At ASCO, City of Hope presented on a number of topics, but some of the most noteworthy involved the first KRAS inhibitor to show anti-tumor activity and the use of CAR T cell therapy in chronic lymphocytic leukemia.

City of Hope investigates a novel therapeutic approach in AML

April 26, 2019 | City of Hope

City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.

City of Hope launches first CAR T cell trial targeting CS1 protein in multiple myeloma

April 26, 2019 | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.